Nuvalent, Inc. (NASDAQ:NUVL) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of Nuvalent, Inc. (NASDAQ:NUVL) have earned an average rating of “Moderate Buy” from the sixteen research firms that are currently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell rating and fifteen have issued a buy rating on the company. The average 12-month price target among analysts that have covered the stock in the last year is $138.3333.

A number of analysts recently commented on NUVL shares. UBS Group reaffirmed a “buy” rating on shares of Nuvalent in a research report on Wednesday, December 17th. Wedbush restated an “outperform” rating and set a $125.00 price objective (up previously from $120.00) on shares of Nuvalent in a report on Monday, November 17th. Robert W. Baird increased their target price on Nuvalent from $112.00 to $158.00 and gave the stock an “outperform” rating in a report on Tuesday, November 18th. The Goldman Sachs Group lifted their price target on shares of Nuvalent from $120.00 to $135.00 and gave the company a “buy” rating in a research report on Tuesday, November 18th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Nuvalent in a report on Thursday.

Insider Activity at Nuvalent

In related news, CEO James Richard Porter sold 9,543 shares of the company’s stock in a transaction dated Tuesday, January 6th. The shares were sold at an average price of $97.16, for a total value of $927,197.88. Following the sale, the chief executive officer owned 278,629 shares in the company, valued at $27,071,593.64. This represents a 3.31% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Henry E. Pelish sold 2,664 shares of the firm’s stock in a transaction dated Tuesday, January 6th. The shares were sold at an average price of $97.17, for a total transaction of $258,860.88. Following the completion of the transaction, the insider directly owned 65,888 shares in the company, valued at approximately $6,402,336.96. The trade was a 3.89% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 934,875 shares of company stock valued at $90,453,154 over the last quarter. 10.20% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the stock. GAMMA Investing LLC grew its holdings in Nuvalent by 47.6% during the fourth quarter. GAMMA Investing LLC now owns 335 shares of the company’s stock worth $34,000 after buying an additional 108 shares in the last quarter. Aster Capital Management DIFC Ltd purchased a new position in Nuvalent during the 3rd quarter worth $38,000. Eastern Bank purchased a new position in Nuvalent during the 3rd quarter worth $52,000. Persistent Asset Partners Ltd bought a new stake in shares of Nuvalent in the 2nd quarter worth $88,000. Finally, Farther Finance Advisors LLC grew its stake in shares of Nuvalent by 9,230.8% in the 2nd quarter. Farther Finance Advisors LLC now owns 1,213 shares of the company’s stock worth $93,000 after acquiring an additional 1,200 shares in the last quarter. Hedge funds and other institutional investors own 97.26% of the company’s stock.

Nuvalent Stock Down 5.0%

Shares of NASDAQ NUVL opened at $106.44 on Monday. The firm has a market cap of $7.74 billion, a PE ratio of -20.01 and a beta of 1.32. The company’s fifty day simple moving average is $105.12 and its 200 day simple moving average is $91.22. Nuvalent has a 12-month low of $55.53 and a 12-month high of $113.01.

Nuvalent (NASDAQ:NUVL) last announced its quarterly earnings data on Thursday, October 30th. The company reported ($1.70) earnings per share for the quarter, missing the consensus estimate of ($1.39) by ($0.31). During the same quarter in the previous year, the business posted ($1.28) EPS. On average, equities analysts predict that Nuvalent will post -3.86 earnings per share for the current year.

Nuvalent Company Profile

Nuvalent, Inc (NASDAQ:NUVL) is a clinical-stage precision oncology company focused on the discovery, development and commercialization of targeted therapies for patients with genetically defined cancers. Founded in 2019 and headquartered in San Diego, California, Nuvalent applies structure-guided drug design to develop small molecule inhibitors that address key oncogenic drivers. The company’s research platform integrates insights from cancer biology, medicinal chemistry and translational science to create therapies with differentiated selectivity and potency against validated targets.

Nuvalent’s lead pipeline candidates include NVL-520, a highly selective RET inhibitor designed to minimize off-target effects, and NVL-655, a potent covalent inhibitor targeting KRAS G12D mutations.